Advertising jury on warnings for medical products
With decision number 7/2013 issued on 8 February 2013, in the case Boheringer Ingeheim Italia S.p.A. v Verelibron S.r.l./Chefaro Pharma Italia S.r.l., the Advertising and Marketing Communication Self-Regulation Authority took position on the interpretation of section 25 of the Self Regulation Code of Marketing Communication relating to the advertisement of medical products and curative treatments. Said provision ‘requires to deliver an express invitation to read the package warnings in advertisements’.
Boheringer claimed that the respondent’s TV commercial for a cough syrup was misleading and not compliant with section 25 of the Code. Boheringer argued that the invitation to read the package warnings was not given orally but with a dateline that was unable to draw consumer’s attention.
If you are registered and logged in to the site, click on the link below to read the rest of the NCTM briefing. If not, please register or sign in with your details below.
News from NCTM
Briefings from NCTM
The European Court of Justice has ruled on the risk of dilution as ground for refusal pursuant to article 8(5) of the regulation number 207/2009 (CTMR).
The Italian Supreme Court has overruled the Court of Appeal’s decision that considered legitimate the use of Ferrari trademarks by an unofficial Ferrari owners’ association.
Analysis from The Lawyer
Being sent to London on secondment is a prized opportunity for associates in European firms